Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents

Journal of the Society for Integrative Oncology

Volumn 6, Issue 3, 2008, Pages 105-109

  Mach, Claire M ^a   Fugii, Hajime ^b   Wakame, Koji ^b   Smith, Judith ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Amino Up Chemical Co   (Japan)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Active hexose correlated compound; Cancer; Inducer; Metabolism; Substrate

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; DOCETAXEL; DOXORUBICIN; IFOSFAMIDE; IMATINIB; INTERFERON; IRINOTECAN; ISOENZYME; KETOCONAZOLE; NATURAL PRODUCT; ONDANSETRON; PACLITAXEL; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; TAMOXIFEN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASIDIOMYCETES; CONTROLLED STUDY; CRYOPRESERVATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER METABOLISM; PROTEIN INDUCTION; RECOMMENDED DRUG DOSE;

AGARICUS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; LIVER; PLANT EXTRACTS; POLYSACCHARIDES;

EID: 51549105072     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2008.0022     Document Type: Article

References (10)

1. Hirose A, Sato E, Fujii H, et al. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 2007;222:152-8.
2. Matsushita K, Kuramitsu U, Ohiro Y, et al. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs 1998;9:343-50.
3. Sun B, Wakame K, Mukoda T, et al. Protective effects of AHCC on carbon tetrachloride induced liver injury in mice. Nat Med 1997; 51:310-5.
4. Wakame K. Protective effect of active hexose correlated compound (AHCC) on onset of diabetes induced by streptozotocin in rats. Biomed Res 1999;20:145-52.
5. Ye S, Ichimura K, Wakame K, Ohe M. Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci 2003;74:593-602.
6. Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 2002;37:78-86.
7. Gao Y, Zhang D, Sun B, et al. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother 2006; 55:1258-66.
8. Crespi CL, Miller VP, Penman BW. Microtiter plate assays from human, drug-metabolizing cytochrome P450s. Analyt Biochem 197;248:188-90.
9. Spierings ELH, Fujii H, Walshe T. A phase I study of the safety and nutritional supplement, active hexose correlated compound, AHCC, in health volunteers. J Nutr Sci Vitaminol 2007;53:536-9.
10. Hellum BH, Zhuohan H, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007; 100:23-30.